Managed Healthcare Executive

FDA Approves First Subcutaneous Version of Keytruda for Adults With Most Solid Tumors

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indic…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
Lupus Foundation of America

Phase III TULIP-SC trial of SAPHNELO® self-administration demonstrates reduction in systemic lupus erythematosus disease activity

AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus ...
Fierce Pharma

Merck scores FDA approval for subcutaneous Keytruda, securing potential blockbuster protection

While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...
Targeted Oncology

FDA Approves Subcutaneous Pembrolizumab for Solid Tumor Indications

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...
CURE

FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Subcutaneous amivantamab every 4 weeks plus lazertinib shows high response rate in EGFR-mutated NSCLC

A new analysis from the PALOMA-2 study shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in ...

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Hea…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s ...
Healio

VIDEO: Subcutaneous mosunetuzumab demonstrates efficacy in marginal zone lymphoma

In this video, Joshua Brody, MD, discusses results from the ongoing phase 2 MorningSun trial of subcutaneous mosunetuzumab as frontline treatment for marginal zone lymphoma.Mosunetuzumab-axgb ...
Oncology Nurse Advisor

Time Savings With Subcutaneous Cancer Drugs May Be “Modest” in the Real World

The study results “highlight how even well-intentioned efforts to save patients’ time may face barriers,” the researchers wrote.
PharmaTimes

Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis

Johnson & Johnson has announced a positive opinion from the CHMP recommending expanded marketing authorisation for TREMFYA ...
The Manila Times

TREMFYA (guselkumab) receives positive CHMP opinion for subcutaneous induction regimen in ulcerative colitis, a first for an IL-23 inhibitor

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,12,13 ...